TABLE 1.

Proportions of subjects with SBA titers of ≥4 against heterologous strains (non-vaccine type) in a subset of subjects in the MenBvac group

Strain (isolation yr)OriginSerogroupPorB (serotype)PorA (subtype)LPS (immunotype)STa complex% of subjects (95% CI) with SBA titers of ≥4 against heterologous strains at the indicated time
Pre-vacc.b (n = 34)6 wk after 2nd dose (n = 34)6 wk after 3rd dose (n = 33)10 mo after 3rd dose (n = 29)6 wk after 4th dose (n = 29)1 yr after 4th dose (n = 29)
LNP20404 (2004)FranceB14P1.7,16L3,7ST-3212 (3-27)53 (35-70)76 (58-89)52 (33-71)90 (73-98)72 (53-87)
N 13/99 (1999)NorwayB4P1.7-2,4L8ST-41/449 (2-24)47 (30-65)70 (51-84)21 (8-40)76 (56-90)34 (18-54)
N 11/03 (2003)NorwayB4P1.7-2,4L3,7ST-28843 (0.074-15)6 (1-20)12 (3-28)17 (6-36)21 (8-40)21 (8-40)
NZ98/254 (1998)New ZealandB4P1.7-2,4L3,7ST-41/449 (2-24)9 (2-24)24 (11-42)17 (6-36)31 (15-51)24 (10-44)
NZ94/167 (1994)New ZealandB4P1.7-2,4L3,7ST-41/4415 (5-31)21 (9-38)30 (16-49)34 (18-54)62 (42-79)41 (24-61)
  • a ST, sequence type.

  • b Pre-vacc., prevaccination.